Ankara, Turkey-based SmartAlpha has received clearance from the U.S. Food and Drug Administration (FDA) for Nerveblox, an AI software designed to assist clinicians during ultrasound-guided nerve blocks.
The software is capable of detecting and highlighting 50 key anatomical structures in real-time to help guide nerve blocks during a broad range of procedures, from cesarean sections and breast surgery to knee and shoulder procedures, as well as during pain relief procedures for fractures and injuries, according to the firm.
Earlier this year, Nerveblox was granted regulatory approvals in Europe, the U.K., and Australia, SmartAlpha said.
